C3 International Inc. Responds to SEC Charges, Vows to Defend Innovative Medical Solution to Prescribing (Rx) Problem
C3 International is committed to vigorously defending its innovative medical solution and reputation against these unexpected charges.
- C3 International is committed to vigorously defending its innovative medical solution and reputation against these unexpected charges.
- C3 International Inc. is proud to introduce Idrasil, a revolutionary cannabis-derived, anhydrous tablet, the first of its kind is designed to offer a new approach to addressing various medical conditions.
- This innovative product has been available to the prescribing community in California, presenting practitioners with an exciting new option to enhance patient care.
- The civil, not criminal, charges filed by the SEC against C3 International and Idrasil are without precedent.